← FDA DRUG APPROVALS

FDA ANDA · ANDA090955

MONTELUKAST SODIUM

Sponsor: TEVA PHARMS

APPLICATION
ANDA090955
TYPE
ANDA
ORIGINAL APPROVAL
2012-08-03
LATEST ACTION
2023-10-04
ROUTE
ORAL
DOSAGE FORM
GRANULE
MARKETING STATUS
Discontinued

Products

MONTELUKAST SODIUMDiscontinued
MONTELUKAST SODIUM EQ 4MG BASE/PACKET · GRANULE · ORAL

Approval history

2023-10-04Labeling · Supplement 14 · standardAP
2023-10-04Labeling · Supplement 15 · standardAP
2019-11-08Labeling · Supplement 12 · standardAP
2019-11-08Labeling · Supplement 10 · standardAP
2019-11-08Labeling · Supplement 13 · standardAP
2015-04-28Labeling · Supplement 7 · standardAP
2015-04-28Labeling · Supplement 6 · standardAP
2013-06-26Labeling · Supplement 5 · standardAP
2013-02-06Labeling · Supplement 4 · standardAP
2012-12-17Labeling · Supplement 2 · standardAP
2012-08-03OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →